MarketScreener Homepage > Equities > NASDAQ OMX COPENHAGEN > Novo Nordisk A/S NOVO B DK0060534915

Report

Delayed NASDAQ OMX COPENHAGEN - 09/25 11:09:59 am
439.4	DKK		+0.48%

09/25

NOVO NORDISK : UBS reiterates its Neutral rating

09/23

NOVO NORDISK A/S : - Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated

09/22

NOVO NORDISK A/S : Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and welltolerated for people with type 2 diabetes in phase 2 trial

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq Omx Copenhagen

09/21/2020	09/22/2020	09/23/2020	09/24/2020	09/25/2020	Date
434.95(c)	437.2(c)	445.5(c)	437.3(c)	439.4(c)	Last
2 181 273	1 851 172	2 507 078	2 396 007	1 562 471	Volume
-0.01%	+0.52%	+1.90%	-1.84%	+0.48%	Change

More quotes

Financials

Sales 2020	128 B 19 942 M 19 942 M
Net income 2020	41 699 M 6 519 M 6 519 M
Net cash position 2020	11 683 M 1 826 M 1 826 M
P/E ratio 2020	24,6x
Yield 2020	2,04%

Sales 2021	136 B 21 271 M 21 271 M
Net income 2021	45 794 M 7 159 M 7 159 M
Net cash position 2021	14 902 M 2 330 M 2 330 M
P/E ratio 2021	21,8x
Yield 2021	2,22%

Capitalization	1 022 B 159 B 160 B
EV / Sales 2020	7,92x
EV / Sales 2021	7,40x
Nbr of Employees	43 526
Free-Float	68,7%

More Financials

Company

Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of...

Sector

Pharmaceuticals

Calendar

10/30

Ergebnisveröffentlichung

More about the company

Notations Surperformance© of Novo Nordisk A/S

Trading Rating :

Investor Rating :

More Ratings

All news about NOVO NORDISK A/S

09/25	NOVO NORDISK : UBS reiterates its Neutral rating	MD
09/23	NOVO NORDISK A/S : - Switching to investigational once-weekly insulin icodec fro..	AQ
09/22	NOVO NORDISK A/S : Switching to investigational once-weekly insulin icodec from ..	PU
09/21	NOVO NORDISK A/S : launches new 100% renewable power target for suppliers	AQ
09/21	NOVO NORDISK A/S : launches new 100% renewable power target for suppliers	PU
09/14	European healthcare stocks hit by Trump drug order	RE
09/14	NOVO NORDISK A/S : – Share repurchase programme	AQ
09/01	NOVO NORDISK A/S : insulin production line launches in Iran	AQ
08/31	NOVO NORDISK A/S : – Share repurchase programme	AQ
08/26	NOVO NORDISK A/S : Disclosure of transaction data related to Novo Nordisk's shar..	PU
08/25	NOVO NORDISK A/S : Karolinska Institutet, St. Erik Eye Hospital and Novo Nordisk..	AQ
08/20	NOVO NORDISK A/S : Q2 2020 conference call presentation	PU
08/20	NOVO NORDISK A/S : Q2 2020 London presentation	PU
08/18	NOVO NORDISK : UBS sticks Neutral	MD
08/17	NOVO NORDISK A/S : Disclosure of transaction data	PU

More news

News in other languages on NOVO NORDISK A/S

09/25	NOVO NORDISK : UBS conserve son opinion neutre
09/25	UBS belässt Novo Nordisk auf 'Neutral' - Ziel 415 Kronen
09/25	TOUR DU MONDE DES INDICES : Tesla-dépendance et irréductibles danois
09/24	NOVO NORDISK : une étude sur les maladies cardiovasculaires
09/21	BOURSE : Chassez la distanciation sociale, elle revient au galop

More news

Analyst Recommendations on NOVO NORDISK A/S

09/25	NOVO NORDISK : UBS reiterates its Neutral rating	MD
08/18	NOVO NORDISK : UBS sticks Neutral	MD
08/14	NOVO NORDISK : Kepler Cheuvreux reaffirms its Neutral rating	MD

More recommendations

Provided by Scoopnest.com

Stock Pick

NOVO NORDISK AS
Global leader in diabetes treatments

More Recommendations

Chart NOVO NORDISK A/S

Duration : Period :

Novo Nordisk A/S Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends NOVO NORDISK A/S

	Short Term	Mid-Term	Long Term
Trends	Bullish	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	25
Average target price	445,67 DKK
Last Close Price	439,40 DKK
Spread / Highest target	19,5%
Spread / Average Target	1,43%
Spread / Lowest Target	-30,6%

Consensus

EPS Revisions

More Estimates Revisions

Managers

Name	Title
Lars Fruergaard Jørgensen	President & Chief Executive Officer
Helge Lund	Chairman
Maziar Mike Doustdar	Executive Vice President-International Operations
Karsten Munk Knudsen	Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen	Chief Science Officer & Executive Vice President

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

NOVO NORDISK A/S	13.64%	159 466



JOHNSON & JOHNSON	-0.14%	383 497
ROCHE HOLDING AG	5.40%	304 339
MERCK & CO., INC.	-8.82%	209 750
PFIZER, INC.	-8.73%	200 326
NOVARTIS AG	-12.61%	190 402

More Results